ACHV News and Press, Achieve Life Sciences Inc. From 06/11/19

CymaBay Therapeutics (NASDAQ: CBAY )  -45%  on disappointing data on NASH candidate seladelpar. More news on: CymaBay Therapeutics, Inc., Achieve Life Sciences, Inc., Beyond Meat, Inc., Stocks on the move, Read more ...

Achieve Life Sciences (NASDAQ: ACHV ) is up  16%  premarket on robust volume in response to results from the Phase 2 ORCA-1 dose-selection study of cytisinicline for smoking cessation. More news on: Achieve Life Sciences, Inc., Healthcare stocks news, Stocks on the move, Cons...

3.0 mg, 3 times daily selected as dose for future clinical development SEATTLE and VANCOUVER, British Columbia , June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced posi...

SEATTLE and VANCOUVER, British Columbia , June 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it enter...

The USPTO has granted Achieve Life Sciences (NASDAQ: ACHV ), a patent (No. 10,300,050) on succinate salt of cytisinicline and use thereof. More news on: Achieve Life Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SEATTLE and VANCOUVER, British Columbia , May 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the Unit...

Achieve Life Sciences, Inc. (ACHV) Q1 2019 Results Conference Call May 15, 2019 04:30 PM ET Company Participants Jaime Xinos - EVP, Commercial Rick Stewart - CEO Dr. Cindy Jacobs - Chief Medical Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann Joh...

In its Q1 report , Achieve Life Sciences (NASDAQ: ACHV ) announces that topline results from the Phase 2b ORCA-1  trial evaluating smoking cessation med cytisinicline should be available by the end of next month. The last study visit by the last enrollee has taken place. More news o...

Achieve Life Sciences (NASDAQ: ACHV ): Q1 GAAP EPS of -$0.88 misses by $0.25 . More news on: Achieve Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SEATTLE and VANCOUVER, British Columbia , May 15, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on...